ATLANTA, Jan. 18, 2022 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it was renaming and rebranding itself to Artivion, Inc., effective immediately. Derived from the words "aorta", "innovation", and "vision", the company's new name and brand reflect its evolution to focus on providing innovative technologies to surgeons who treat patients with aortic disease. In conjunction with these changes, effective January 24, 2022, the company will also change its ticker symbol on the New York Stock Exchange to "AORT" from "CRY."
"Through a combination of legacy products and strategic acquisitions and divestitures over the last five years, we have transformed from a tissue and adhesives focused company to one with a premier portfolio of aortic products," said Pat Mackin, Chairman, President and Chief Executive Officer of Artivion. "Today marks an important milestone for our company. We look forward to embarking on our next chapter as a leader in developing simple, elegant solutions to address cardiac and vascular surgeons' most difficult clinical challenges in treating patients with aortic disease."
Artivion will discuss its business, its strategy, and the rebrand at an Investor & Analyst Day on March 23, 2022, in New York City. Details of the event will be provided at a later date.
About Artivion, Inc.Headquartered in suburban Atlanta, Georgia, Artivion, Inc. (Artivion) is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult clinical challenges in treating patients with aortic diseases. This multinational company's four major groups of products include: aortic stents and stent grafts, prosthetic heart valves, cryopreserved cardiac and vascular allografts, and surgical sealants. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.artivion.com, accessible by the end of day today.
Contacts:
CryoLife D. Ashley Lee Executive Vice President, Chief Financial Officer and Chief Operating OfficerPhone: 770-419-3355 | Gilmartin Group LLCBrian Johnston / Lynn LewisPhone: 631-807-1986investors@cryolife.com |
View original content to download multimedia:https://www.prnewswire.com/news-releases/cryolife-announces-corporate-rebranding-and-changes-name-to-artivion-301462581.html
SOURCE CryoLife, Inc.; Artivion, Inc.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。